The potential markers of endocrine resistance among HR+ /HER2+ breast cancer patients.

K ChenJ QuanJ YangZhe-Ling Chen

Published in: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (2019)

This study analyzed the clinical characteristics and survival of patients with HR+/HER2+ breast cancer as a special subgroup. ERBB2, IKZF3, LASP1, and CDK12 were the potential markers of the resistance of endocrine therapy, and they will provide new strategies for clinicians.

Keyphrases

acute lymphoblastic leukemia
human health
palliative care
tyrosine kinase
risk assessment
free survival
study protocol
smoking cessation
chemotherapy induced